Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127763001 | 12776300 | 1 | I | 20160919 | 20160923 | 20160923 | EXP | IT-JNJFOC-20160914906 | JANSSEN | BOSETTI R, FERRANDINA G, MARNEFFE W, SCAMBIA G, VEREECK L. COST-EFFECTIVENESS OF GEMCITABINE VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN FOR RECURRENT OR PROGRESSIVE OVARIAN CANCER: COMPARING CHEMOTHERAPY WITH NANOTHERAPY. NANOMEDICINE 2014;9/14:2175-2186. | 0.00 | Y | 0.00000 | 20160923 | OT | BE | BE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127763001 | 12776300 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | U | U | 50718 | 40 | MG/M**2 | LIPOSOME INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127763001 | 12776300 | 1 | Ovarian cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127763001 | 12776300 | OT |
| 127763001 | 12776300 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127763001 | 12776300 | Alopecia | |
| 127763001 | 12776300 | Anaemia | |
| 127763001 | 12776300 | Decreased appetite | |
| 127763001 | 12776300 | Diarrhoea | |
| 127763001 | 12776300 | Fatigue | |
| 127763001 | 12776300 | Hepatotoxicity | |
| 127763001 | 12776300 | Leukopenia | |
| 127763001 | 12776300 | Mucosal inflammation | |
| 127763001 | 12776300 | Nausea | |
| 127763001 | 12776300 | Neurotoxicity | |
| 127763001 | 12776300 | Neutropenia | |
| 127763001 | 12776300 | Palmar-plantar erythrodysaesthesia syndrome | |
| 127763001 | 12776300 | Thrombocytopenia | |
| 127763001 | 12776300 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |